References
1
Eisenhofer G et al. (2003) Biochemical diagnosis of pheochromocytoma: how to
distinguish true- from false-positive test results. J Clin Endocrinol Metab 88: 2656–2666
2
Janetschek G et al. (1998) Laparoscopic surgery for pheochromocytoma: adrenalectomy,
partial resection, excision of paragangliomas. J Urol 160: 330–334
3
Neumann HPH et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma.
N Engl J Med 346: 1459–1466
4
Plouin P-F and Gimenez-Roqueplo A-P (2006) The genetic basis of pheochromocytoma:
who to screen and how? Nat Clin Pract Endocrinol Metab 2: 60–61
5
Jimenez C et al. (2006) Review: should patients with apparently sporadic
pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol
Metab 91: 2851–2858
6
Benn DE et al. (2005) Clinical presentation and penetrance of
pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91: 827–836
7
Pacak K et al. (2007) Pheochromocytoma: recommendations for clinical practice from
the First International Symposium. Nat Clin Pract Endocrinol Metab 3: 92–102
8
Baysal B et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in
hereditary paraganglioma. Science 287: 848–851
9
Lee S et al. (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial
pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155–167
10
Selak MA et al. (2005) Succinate links TCA cycle dysfunction to oncogenesis by
inhibiting HIF-[alpha] prolyl hydroxylase. Cancer Cell 7: 77–85
11
Gottlieb E and Tomlinson IP (2005) Mitochondrial tumour suppressors: a genetic and
biochemical update. Nat Rev Cancer 5: 857–866